After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...